Dexmedetomidine as an adjunctive treatment for acute asthma

Hassan Motamed¹,², Arash Forouzan¹,², Meisam Moezzi¹,², Hossein Alizadeh¹,²

¹Department of Emergency Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
²Air Pollution and Respiratory Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Objective This study aimed to compare the efficacy of using dexmedetomidine with salbutamol and salbutamol nebulization alone in patients with acute exacerbation of asthma presenting to the emergency department.

Methods This clinical trial included 60 patients, in the age range of 18 to 55 years, with signs of bronchospasm presenting to the emergency department. In the intervention group, dexmedetomidine 0.5 µg/kg was injected intravenously and three doses of salbutamol nebulization were administered over 60 minutes. In the control group, salbutamol nebulization was administered for 60 minutes three times. The patient's clinical status, based on clinical symptoms, consciousness, speech, breathing rate, heart rate, and blood pressure were recorded before the intervention, and peak expiratory flow rate and forced expiratory volume in 1 second were measured at 20, 40, and 60 minutes after intervention. Patients who did not respond to the intervention were excluded from the study within 60 minutes.

Results The increased mean forced expiratory volume in 1 second and mean peak expiratory flow rate were found to be similar in both groups during the treatment (P = 0.304). The mean systolic and diastolic blood pressure recorded at 40 and 60 minutes were significantly lower in the intervention group. During this study, no patient was excluded before 60 minutes.

Conclusion Administration of dexmedetomidine in addition to standard salbutamol treatment has no beneficial effect in patients with acute asthma attacks and merely causes hypotension in patients.

Keywords Albuterol; Bronchial diseases; Asthma; Dexmedetomidine; Emergency service, hospital

What is already known
The most effective treatment for acute exacerbation of asthma is a short-acting inhaled beta-agonist.

What is new in the current study
Administration of dexmedetomidine in addition to standard salbutamol treatment has no effect on the improvement of severity in patients with acute asthma attacks and merely causes hypotension in them.
INTRODUCTION

Chronic lung diseases are a common cause of disability and death worldwide. Asthma is one of the most common respiratory disorders contributing to several deaths annually. It is reported that, globally, around 35.3% of people have asthma and at least 25% of the annual emergency visits to hospitals are associated with asthma. Factors affecting asthma involve heredity, urbanization, air pollution, exposure to cigarette smoke, and unhealthy food habits.

Recurrent asthma is characterized by airway hypersensitivity, mucosal edema, and inflammation in the airways. Medications used in asthma are bronchodilators (provide immediate relief of symptoms by relaxing the smooth muscle lining of the bronchi) and inhaled steroids (inhibit the underlying inflammatory process). Bronchodilators are beta-agonists with no effect on the underlying inflammation. The most effective treatment for acute exacerbation of asthma is a short-acting inhaled beta-agonist (salbutamol) administered through a nebulizer, spray, or spacer.

It has been recently reported that the use of dexmedetomidine, with its sedative effect, could play a role in faster and more effective treatment of an acute asthma attack. Dexmedetomidine, a new drug belonging to the benzodiazepine family, has minimal respiratory depression effects unlike other benzodiazepines, and with its sedation properties, reduces the patient’s agitation during acute asthma, thereby lowering the respiratory distress and leading to faster recovery. It is a central agonist of the alpha-adrenoreceptor that activates protein G in the locus coeruleus of the brainstem. It has a calming effect and reduces the release of norepinephrine. This, in turn, will reduce the respiratory distress and lower the blood pressure, heart rate and respiratory rate (RR). The half-life of this drug in the body ranges from 6 minutes to 2 hours; the short half-life helps in lessening the side effects.

Inhaled corticosteroids are used as first-line treatment for patients with persistent asthma, whose symptoms cannot be controlled with short-acting beta-agonists alone. The goals in asthma treatment are to prevent symptoms, restore normal lung function, help the patient regain normal activity, prevent recurrences, provide an optimal drug regimen with minimal side effects, and ensure patient and family satisfaction.

The purpose of this study was to compare the efficacy of using dexmedetomidine with salbutamol and salbutamol nebulization alone in patients with acute asthma referred to the emergency department, and determine the extent of improvement in respiratory distress when using this treatment.

METHODS

Study design

This was a clinical trial including patients with signs of bronchospasm who presented to the emergency department of our hospital. The study was registered with the IRCT clinical trial registry (IRCT20131118015446N14), and received approval from Ahvaz Jundishapur University of Medical Sciences ethical committee (IR. AJUMS. REC.1397.021). Informed consent was obtained in written form from the enrolled patients.

Participants

Inclusion criteria

Patients in the age range of 18 to 55 years with acute asthma attack were included after obtaining their consent for participation in the study. Patients had a history of asthma or were confirmed by spirometry within 2 weeks of having a diagnosis of asthma.

Exclusion criteria

The exclusion criteria were as follows: dissatisfaction with the study, failure to respond to treatment, worsening clinical status requiring additional treatment such as magnesium sulfate, injectable epinephrine or intubation, use of intermittent positive pressure, and patient refusal to cooperate. Further, patients with underlying diseases having asthma-like manifestations, chronic bronchitis, coronary heart disease, cardiac arrhythmias, smokers with a history of smoking 10 packs/year or more, and use of beta-agonist nebulizer 6 hours before visiting the ED were also excluded.

Interventions

Patients were randomly divided into the intervention and the control groups. History and clinical examination of patients, state of consciousness, use of lateral respiratory muscles, wheezing, and parameters including RR, pulmonary function, blood pressure, and oxygen saturation were evaluated prior to the intervention.

In the intervention group, 0.5 µg/kg of dexmedetomidine was injected intravenously and salbutamol nebulization was administered three times over 60 minutes. In the control group, salbutamol nebulization was administered three times over 60 minutes.

After measuring the peak expiratory flow rate (PEFR) and forced expiratory volume in 1 second (FEV1), the patient’s clinical status was assessed before the intervention, and at 20, 40, and 60 minutes after the intervention, based on clinical symptoms, consciousness, speech, breathing rate, heart rate, and blood pressure. Blood and pulse oxygen saturation percentages were also recorded at these intervals.
Randomization
Eligible patients were randomly divided into two groups such that there were an equal number of patients in both groups. Researchers were blinded in assigning individuals to the groups. This division was done using four permutation blocks.

Sample size
This was a phase II clinical study with a sample size of 50 patients, the minimum sample size required for such a study as per literature.14

Statistical methods
All analyses were performed using IBM SPSS Statistics ver. 22 (IBM Corp., Armonk, NY, USA). Descriptive data were analyzed with mean ± standard deviation. Quantitative data between the two groups were compared using the independent t-test and Mann-Whitney test, based on the normality of the data. The level of statistical significance was considered to be less than 0.05.

RESULTS
A total of 60 patients with an acute attack of asthma were enrolled (30 patients received intravenous dexmedetomidine and salbutamol nebulization, and 30 patients received salbutamol nebulization alone). Of them, 30 patients (50%) were male and the mean age of the patients was 35.2 ± 9.29 years (Table 1). Increases in mean FEV1 (P = 0.304) and mean PEFR (P = 0.618) were found to be similar in both groups during treatment (Table 2). There was no statistically significant difference in the mean pulse rate of patients before the intervention and during the first hour (P < 0.001). The mean RR in the patients during the first hour was not significantly different, and only a slight difference was seen before the intervention (Table 2).

The mean systolic blood pressure recorded at 40 and 60 minutes was significantly lower in the intervention group than in the control group (P = 0.012). However, at baseline, the blood pressure was significantly higher in this group than in the control group (P = 0.036). The mean diastolic blood pressure from 40 to 60 minutes was significantly lower in the intervention group than in the control group (P = 0.007), while at baseline, it was significantly higher in the control group (P = 0.040). Mean arterial blood pressure slightly decreased in the intervention group and increased in the control group (P = 0.040).

### Table 1. Basic characteristics of patients

| Variable                      | Dexmedetomidine+ salbutamol (n = 30) | Salbutamol only (n = 30) | P-value |
|-------------------------------|--------------------------------------|--------------------------|---------|
| Age (yr)                      | 34.8 ± 10.0                          | 35.2 ± 8.7               | 0.858   |
| Sex, male                     | 16 (53.3)                            | 14 (46.7)                | 0.606   |
| Asthma duration (yr)          |                                      |                          |         |
| > 1                           | 1 (3.3)                              | 4 (13.3)                 | 0.115   |
| 1–5                           | 28 (93.3)                            | 22 (73.3)                |         |
| < 5                           | 1 (3.3)                              | 4 (13.3)                 |         |
| Admission to hospital         |                                      |                          | 0.492   |
| Yes                           | 0                                    | 2 (6.7)                  |         |
| No                            | 30 (100)                             | 28 (93.3)                |         |
| Medication sensitivity        |                                      |                          | 0.237   |
| Yes                           | 0                                    | 3 (10)                   |         |
| No                            | 30 (100)                             | 27 (90)                  |         |

Values are presented as mean ± standard deviation or number (%).

### Table 2. Studied variables during treatment in both groups

| Variable                      | Dexmedetomidine+ salbutamol (n = 30) | Salbutamol only (n = 30) | P-value |
|-------------------------------|--------------------------------------|--------------------------|---------|
| FEV1                          |                                      |                          | 0.304   |
| Before intervention           | 106.4 ± 16.5                         | 107.8 ± 16.9             |         |
| 20th min                      | 124.3 ± 22.6                         | 122.2 ± 22.1             |         |
| 40th min                      | 147.9 ± 36.0                         | 136.4 ± 27.2             |         |
| 60th min                      | 165.2 ± 40.5                         | 146.6 ± 29.1             |         |
| PEFR                          |                                      |                          | 0.618   |
| Before intervention           | 164.1 ± 40.7                         | 172.8 ± 36.4             |         |
| 20th min                      | 201.3 ± 40.8                         | 198.1 ± 42.9             |         |
| 40th min                      | 235.4 ± 42.1                         | 225.5 ± 47.2             |         |
| 60th min                      | 266.2 ± 50.4                         | 248.8 ± 51.2             |         |
| Pulse rate (/min)             |                                      |                          | <0.001  |
| Before intervention           | 86.6 ± 7.8                           | 84.6 ± 7.7               |         |
| 20th min                      | 94.6 ± 9.5                           | 92.7 ± 8.3               |         |
| 40th min                      | 104.4 ± 11.7                         | 100.4 ± 11.1             |         |
| 60th min                      | 115.3 ± 13.2                         | 109.1 ± 12.1             |         |
| RR (/min)                     |                                      |                          | <0.001  |
| Before intervention           | 27.5 ± 2.3                           | 26.3 ± 2.1               |         |
| 20th min                      | 23.3 ± 2.4                           | 23.1 ± 1.7               |         |
| 40th min                      | 20.0 ± 1.9                           | 19.9 ± 1.6               |         |
| 60th min                      | 17.6 ± 1.8                           | 17.9 ± 2.0               |         |
| SBP (mmHg)                    |                                      |                          | 0.012   |
| Before intervention           | 131.0 ± 13.3                         | 123.3 ± 9.6              |         |
| 20th min                      | 125.8 ± 12.9                         | 123.0 ± 9.15             |         |
| 40th min                      | 114.3 ± 12.2                         | 122.7 ± 10.2             |         |
| 60th min                      | 109.1 ± 13.2                         | 121.7 ± 9.5              |         |
| DBP (mmHg)                    |                                      |                          | 0.007   |
| Before intervention           | 84.1 ± 5.7                           | 80.7 ± 4.7               |         |
| 20th min                      | 80.5 ± 5.5                           | 80.2 ± 4.8               |         |
| 40th min                      | 75.5 ± 5.3                           | 79.8 ± 5.5               |         |
| 60th min                      | 72.3 ± 6.3                           | 79.5 ± 4.7               |         |
| O2 saturation (%)             |                                      |                          | 0.640   |
| Before intervention           | 90.8 ± 1.3                           | 91.1 ± 1.0               |         |
| 20th min                      | 92.4 ± 1.3                           | 92.4 ± 1.1               |         |
| 40th min                      | 93.9 ± 1.2                           | 93.8 ± 1.1               |         |
| 60th min                      | 95.3 ± 1.0                           | 94.9 ± 1.4               |         |

Values are presented as mean ± standard deviation.
FEV1, forced expiratory volume in 1 second; PEFR, peak expiratory flow rate; RR, respiratory rate; SBP, systolic blood pressure; DBP, diastolic blood pressure.
Dexmedetomidine management of acute asthma attack

In a case report of an 11-year-old child with COPD undergoing carotid artery stenting, the use of dexmedetomidine reduced respiratory depression and decreased blood pressure and heart rate. A study by Xuan et al.19 aimed to investigate the bronchial effects of alpha 2-adrenoceptor agonists. Inhalational alpha 2-agonists decreased the rapid bronchial reaction to allergens while intensifying the bronchial reaction to histamine, thereby increasing the symptoms. Rilmenidine, a new derivative of oxazoline, has fewer central effects compared to clonidine. In patients with asthma, short-term administration results in moderate improvement of bronchial obstruction and only partial protective action against various nonspecific stimulants or allergens, slightly enhancing the beneficial effects of beta 2-agonists. However, in our study, dexmedetomidine, a type of alpha 2-adrenoceptor agonist, had no observed effect on the severity of asthma.

Our study has some limitations. While dexmedetomidine is a novel treatment option being considered for an acute asthma attack, there are no sufficient studies and clinical trials to compare with the results of our study. The small sample size and nonparametric statistical analysis are other limitations of the study.

In summary, this study demonstrated that the administration of dexmedetomidine along with salbutamol nebulization had no beneficial effect in acute attacks of asthma, and it also led to hypotension in the patients. Therefore, we recommend that dexmedetomidine should not be included in the treatment of acute asthma.

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

ACKNOWLEDGMENTS

This study was financially supported by the Office of Vice- Chancellor for Technology and Research Development of Jundishapur Medical Sciences University, Ahvaz, Southwest Iran as part of Hossein Alizadeh’s thesis under the research code APRD-9701.

REFERENCES

1. Jackson DJ, Hartert TV, Martinez FD, Weiss ST, Fahy JV. Asthma: NHLBI workshop on the primary prevention of chronic lung diseases. Ann Am Thorac Soc 2014;11 Suppl 3:S139–45.
2. Lundback B, Backman H, Lotvall J, Ronmark E. Is asthma prevalence still increasing? Expert Rev Respir Med 2016;10:39–51.
3. Hekking PP, Wener RR, Amelink M, Zwinderman AH, Bouvy
11. Durack J, Lynch SV, Nariya S, et al. Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment. J Allergy Clin Immunol 2017;140:63-75.

12. Calhoun WJ, Haselkorn T, Miller DP, Omachi TA. Asthma exacerbations and lung function in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol 2015;136:1125-7.

13. Jat KR, Khairwa A. Levalbuterol versus albuterol for acute asthma: a systematic review and meta-analysis. Pulm Pharmacol Ther 2013;26:239-48.

14. Lee SH, Kim N, Lee CY, Ban MG, Oh YJ. Effects of dexmedetomidine on oxygenation and lung mechanics in patients with moderate chronic obstructive pulmonary disease undergoing lung cancer surgery: a randomised double-blinded trial. Eur J Anaesthesiol 2016;33:275-82.

15. Groeben H, Mitzner W, Brown RH. Effects of the alpha2-adrenoceptor agonist dexmedetomidine on bronchoconstriction in dogs. Anesthesiology 2004;100:359-63.

16. Lang Y, Wang TL, Wu XM, Ding LG. Application of sedation with a low dose of dexmedetomidine during intrathecal anesthesia in elderly patients. Zhonghua Yi Xue Za Zhi 2011;91:1953-6.

17. DeMuro JP, Mongelli MN, Hanna AF. Use of dexmedetomidine to facilitate non-invasive ventilation. Int J Crit Illn Inj Sci 2013;3:274-5.

18. Venn M, Newman J, Grounds M. A phase II study to evaluate the efficacy of dexmedetomidine for sedation in the medical intensive care unit. Intensive Care Med 2003;29:201-7.

19. Cata JP, Folch E. Dexmedetomidine as sole sedative during percutaneous carotid artery stenting in a patient with severe chronic obstructive pulmonary disease. Minerva Anestesiol 2009;75:668-71.

20. Xuan AT, Lockhart A. Bronchial effects of alpha 2-adrenoceptor agonists and of other antihypertensive agents in asthma. Am J Med 1989;87:345-7.